Shi Ming Tu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Cancer: a "stem-cell" disease?
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030 3721, USA
    Cancer Cell Int 13:40. 2013
  2. pmc Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis
    S M Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Box 1374, 1155 Pressler Street, Houston, TX 77030 3721, USA
    Br J Cancer 107:646-51. 2012
  3. doi request reprint Prostate cancer stem cells
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, TX 77030 3721, USA
    Clin Genitourin Cancer 10:69-76. 2012
  4. doi request reprint Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77239 1439, USA
    J Clin Oncol 27:3319-24. 2009
  5. ncbi request reprint Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2872-80. 2009
  6. ncbi request reprint Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 8:341-51. 2010
  7. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
  8. ncbi request reprint Current trials using bone-targeting agents in prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:35-9. 2008
  9. ncbi request reprint Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
  10. ncbi request reprint Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007

Detail Information

Publications54

  1. pmc Cancer: a "stem-cell" disease?
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030 3721, USA
    Cancer Cell Int 13:40. 2013
    ..Remarkably, many crucial signal pathways in a malignant cell involve "stem-ness" genes. The prevalence of stem-ness in cancer suggests that cancer has a stem-cell origin and is a stem-cell disease...
  2. pmc Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis
    S M Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Box 1374, 1155 Pressler Street, Houston, TX 77030 3721, USA
    Br J Cancer 107:646-51. 2012
    ..Patients with prostate cancer tend to die from bone metastases. Until now, no evidence has shown that Paget's disease of bone (PDB) affects the progression of bone metastasis or overall survival of patients with prostate cancer...
  3. doi request reprint Prostate cancer stem cells
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, TX 77030 3721, USA
    Clin Genitourin Cancer 10:69-76. 2012
    ..Ultimately, the stem cell theory of cancers will affect how we practice clinical oncology: our diagnosis, monitoring, and therapy of prostate and other cancers...
  4. doi request reprint Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77239 1439, USA
    J Clin Oncol 27:3319-24. 2009
    ..We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC)...
  5. ncbi request reprint Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2872-80. 2009
    ..The authors of this report investigated the clinical outcome of patients who had prostate ductal adenocarcinoma after primary radical prostatectomy or radiotherapy...
  6. ncbi request reprint Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 8:341-51. 2010
    ....
  7. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
    ..We assessed the rate of bone marrow failure in patients with prostate cancer who had received a dose of strontium-89...
  8. ncbi request reprint Current trials using bone-targeting agents in prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:35-9. 2008
    ..If so, targeting cancer stem cells or the onco-niche may offer another way to improve treatment of prostate cancer bone metastasis...
  9. ncbi request reprint Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
    ..To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa...
  10. ncbi request reprint Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007
    ..The objective of the current study was to determine the clinical variables that predict this adverse outcome...
  11. ncbi request reprint Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer
    Philippe E Spiess
    Department of Urologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1483-90. 2006
    ..The aim of the present study was to evaluate the authors' PC-RPLND experience and identify predictors of outcome in these patients...
  12. ncbi request reprint Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1503-10. 2006
    ..The objective of this study was to determine whether the presence of viable tumor in the surgical specimen could be predicted...
  13. ncbi request reprint Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
    ....
  14. ncbi request reprint Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ..The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases...
  15. ncbi request reprint Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:131-8. 2007
    ..We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients...
  16. ncbi request reprint A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003
    ..The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma...
  17. ncbi request reprint Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 70:1173-8. 2007
    ....
  18. ncbi request reprint Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:561-7. 2003
    ....
  19. ncbi request reprint Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow
    Funda Vakar-Lopez
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pathol 203:688-95. 2004
    ..These observations indicate that MDA-BF-1 is up-regulated in metastatic PCa and raise the interesting possibility that MDA-BF-1 may play a role in the metastasis and progression of PCa, particularly in bone...
  20. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  21. ncbi request reprint Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
    ..Furthermore, the complicated dosing schedule and toxic effects of the regimen precluded its routine use in the treatment of urothelial carcinoma...
  22. doi request reprint Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib
    Paul Mathew
    Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 68:889-96. 2011
    ..Phase II study of tandutinib was conducted to assess the effects of a continuously administered highly potent PDGFR inhibitor in this disease state...
  23. ncbi request reprint Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
    Christos N Papandreou
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 0427, Houston, TX 77030, USA
    J Clin Oncol 22:2108-21. 2004
    ....
  24. ncbi request reprint Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1361-7. 2002
    ..The purpose of this study was to compare the response rates and overall survival of patients with metastatic or unresectable urothelial cancer treated with these two chemotherapy regimens...
  25. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  26. ncbi request reprint Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases
    Alejandro Luina Contreras
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Hum Pathol 41:832-7. 2010
    ..Our findings suggest that the presence of an angiosarcomatous component in mediastinal germ cell tumor, even in a small amount, is associated with a poor clinical outcome...
  27. ncbi request reprint Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level
    Dan Leibovici
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:198-204. 2007
    ..Occasionally, PC progression can occur despite low or undetectable PSA levels. The authors report on the clinical and pathologic characteristics of patients who experienced PC progression with undetectable or low PSA levels...
  28. ncbi request reprint Clinically atypical seminomas with yolk sac tumor features
    Avik Som
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Can J Urol 20:6860-7. 2013
    ..We explored the possibility that these seminomas are a unique clinical and biologic entity with intrinsic yolk sac tumor (YST) features...
  29. pmc Platinum-based chemotherapy for variant castrate-resistant prostate cancer
    Ana M Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 3721, USA
    Clin Cancer Res 19:3621-30. 2013
    ....
  30. ncbi request reprint Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:1330-4; discussion 1334. 2007
    ..We defined the growth rate and reviewed our experience in the surgical management of growing teratoma syndrome in patients with nonseminomatous germ cell tumors...
  31. ncbi request reprint Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2610-7. 2002
    ..Despite the proximity, prostate carcinoma seldom metastasizes to the penis or testis...
  32. pmc Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience
    Alan J Rodney
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 30:879-85. 2012
    ..Primary mediastinal germ-cell tumors are rare, and the effect of newer drugs and treatment strategies in this disease on overall survival is not known. We retrospectively assessed treatment outcomes at a single institution...
  33. pmc Recurrent seminomas: clinical features and biologic implications
    Avik Som
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 30:494-501. 2012
    ..We also wished to test whether these tumors expressed any specific biomarkers that might distinguish them as a unique subtype of seminoma...
  34. pmc Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma
    George E Manoukian
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77230, USA
    Clin Genitourin Cancer 9:81-8. 2011
    ..This pilot trial evaluated the efficacy and safety of combining a bisphosphonate and a statin in patients with RCC metastatic to bone...
  35. doi request reprint Multisystem crisis in a patient with presumptive renal cell carcinoma
    Mehmet A Bilen
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:128-30. 2008
    ..Prompt diagnosis and appropriate treatments could improve the performance status and quality of life of such patients...
  36. ncbi request reprint Patient survival after surgery for osseous metastases from renal cell carcinoma
    Patrick P Lin
    Department of Orthopaedic Oncology, The University of Texas M D Anderson Cancer Center, Unit 408, P O Box 301402, Houston, TX 77230, USA
    J Bone Joint Surg Am 89:1794-801. 2007
    ..The goal of this retrospective study was to evaluate factors that may affect survival after surgical treatment of metastases of renal cell carcinoma...
  37. ncbi request reprint Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Urol Oncol 24:487-91. 2006
    ..We conclude that single-agent capecitabine has minimal activity for the treatment of metastatic RCC...
  38. ncbi request reprint The central role of osteoblasts in the metastasis of prostate cancer
    Michel B Choueiri
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Metastasis Rev 25:601-9. 2006
    ..This review discusses the possible mechanisms of PCa bone metastasis and highlights the essential role of osteoblasts in the metastasis of PCa to bone...
  39. ncbi request reprint Targeting prostate cancer bone metastases
    Christopher Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:785-8. 2003
  40. ncbi request reprint Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
    ..8 to 17.1 months), with a 15.9-month median survival for 3 patients with poor performance status and visceral metastases. Further clinical investigation of the biological effect of IL-2 in urothelial carcinoma may be warranted...
  41. ncbi request reprint Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  42. ncbi request reprint Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection
    Robert S Svatek
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1310-7. 2009
    ....
  43. pmc Stem cell origin of testicular seminoma
    Avik Som
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
    Clin Genitourin Cancer 11:489-94. 2013
    ..We hypothesized that distinct cancer subtypes arise from unique cancer-initiating cells. By performing a microarray meta-analysis of seminomas and spermatogonial stem cells, we investigated a putative cell of origin for seminoma...
  44. ncbi request reprint Stem-cell origin of metastasis and heterogeneity in solid tumours
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 3:508-13. 2002
    ..Further investigation of the role of stem cells in the development of cancer may lead to the discovery of novel diagnostic tools, prognostic markers, and therapeutic targets in the battle against cancer...
  45. ncbi request reprint Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy
    Bita Esmaeli
    Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:504-7. 2003
    ..The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition...
  46. pmc Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases
    Charles C Guo
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Am J Surg Pathol 33:1173-8. 2009
    ..However, patients with a SC in the metastasis have an increased risk of mortality...
  47. ncbi request reprint Clinical aspects of bone metastases in prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Treat Res 118:23-46. 2004
  48. ncbi request reprint Multilocular cystadenoma and cystadenocarcinoma of the prostate
    Tomasz Tuziak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 25:19-25. 2007
    ..Multicystic prostatic tumors are rare, with only a few reported cases of prostatic cystadenoma and cystadenocarcinoma in the scientific literature...
  49. ncbi request reprint Biology and clinical management of prostate cancer bone metastasis
    Xiang cang Ye
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Front Biosci 12:3273-86. 2007
    ....
  50. ncbi request reprint The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients
    Sriram Yennurajalingam
    Department of Palliative Care and Rehabilitation Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Palliat Med 15:20-4. 2012
    ..The aim of this retrospective study was to describe the impact of an outpatient palliative care (PC) consultation on symptoms in patients with advanced prostate cancer...
  51. pmc Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients
    Fernanda I Staquicini
    David H Koch Center, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 108:18637-42. 2011
    ..These findings provide vascular molecular markers for biotechnology and medical applications...
  52. doi request reprint Surgical management of prostate cancer metastatic to the spine
    Brian J Williams
    Department of Neurosurgery, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Neurosurg Spine 10:414-22. 2009
    ..In this study, a series of patients undergoing spinal surgery for metastatic prostate cancer were reviewed to identify predictors of survival and functional outcome...
  53. ncbi request reprint Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Shi Ming Tu
    J Natl Cancer Inst 95:1174-5; author reply 1175. 2003
  54. pmc Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells
    Chien Jui Cheng
    Department of Pathology, Taipei Medical University and Hospital, Taipei, Taiwan
    Mol Cancer Res 5:675-84. 2007
    ..We speculate that nuclear localization of ErbB-3 may aid prostate cancer cell survival during androgen ablation and progression of prostate cancer in bone...